Drugs / Gusperimus

Trials 3 · a red edge is where a trial was stopped

200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/21 trial
Phase 1/2 NCT00709722 Oct 2003 → Apr 2007 lupus nephritis Nippon Kayaku Co., Ltd. Completed No outcome recorded
Phase 21 trial
Phase 2 NCT00530075 Dec 2003 → Feb 2006 granulomatosis with polyangiitis Nippon Kayaku Co., Ltd. Completed No outcome recorded
Phase 31 trial
Phase 3 NCT01446211 Nov 2011 → Nov 2012 granulomatosis with polyangiitis Nordic Pharma SAS Terminated No outcome recorded

Evidence & citations 11 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as Gusperimus ClinicalTrials.gov intervention name — accepted as the source's own label NCT01446211
1

NCT00530075

Known as 15-deoxyspergualin trihydrochloride ChEMBL registry synonym — accepted as the source's own label CHEMBL406117
Known as BMS-181173 ChEMBL registry synonym — accepted as the source's own label CHEMBL406117
Known as BMY-42215-1 ChEMBL registry synonym — accepted as the source's own label CHEMBL406117
Known as Gusperimus hydrochloride ChEMBL registry synonym — accepted as the source's own label CHEMBL406117
Known as GUSPERIMUS TRIHYDROCHLORIDE ChEMBL registry synonym — accepted as the source's own label CHEMBL406117
Known as NKT-01 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00709722
Known as NSC-356894 ChEMBL registry synonym — accepted as the source's own label CHEMBL406117
Known as Spanidin ChEMBL registry synonym — accepted as the source's own label CHEMBL406117
Modality Small molecule CHEMBL406117
Route Subcutaneous “self-administered by subcutaneous injection” NCT00530075